Back to top
more

POLARITYTE INC. - COMMON STOCK (PTE)

(Delayed Data from NSDQ)

$8.57 USD

8.57
1,046,321

-1.12 (-11.56%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.54 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

RegenETP, Inc. [PTE]

Reports for Purchase

Showing records 1 - 16 ( 16 total )

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 1

01/03/2023

Company Report

Pages: 5

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 2

03/31/2022

Company Report

Pages: 6

Study in DFU Patients to Initiate Imminently; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 3

11/12/2021

Company Report

Pages: 6

Awaiting Regulatory Clarity on SkinTE; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 4

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PTE

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 5

08/13/2021

Company Report

Pages: 6

SkinTE IND filed; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 6

05/14/2021

Company Report

Pages: 6

Awaiting SkinTE IND in 2H21; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 7

03/31/2021

Company Report

Pages: 7

SkinTE IND to Be Filed in 2H21; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 8

08/07/2020

Company Report

Pages: 7

Waiting for Clarity on SkinTE?s Regulatory Pathway; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 9

07/29/2020

Daily Note

Pages: 4

Positive Interim DFU Data; Questions Regarding SkinTE Future Remain; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 10

05/12/2020

Company Report

Pages: 6

Waiting for Regulatory Clarity on SkinTE; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 11

05/04/2020

Company Report

Pages: 6

Strategy Shift Adds Uncertainties; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 12

04/23/2020

Daily Note

Pages: 3

Expect COVID-19 Impact on Revenues to Be Temporary; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 13

03/13/2020

Company Report

Pages: 7

Light 4Q19 but Growth Is Expected to Return; Lower PT to $5.00 on Dilution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 14

11/13/2019

Company Report

Pages: 6

SkinTE Sales Continue to Ramp; Clinical Updates in 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 15

08/09/2019

Company Report

Pages: 7

Promising Growth in SkinTE Sales; Clinical Updates in Near Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: RegenETP, Inc.

Industry: Medical - Drugs

Record: 16

07/08/2019

Company Report

Pages: 18

Initiate With Buy and an $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 50.00

Research Provided by a Third Party
// eof